Lumito

4.20 SEK

-15.83 %

Less than 1K followers

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-15.83 %

-39.13 %

-40.00 %

-47.50 %

-85.73 %

-95.18 %

-98.93 %

-99.23 %

-98.28 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Market cap

14.45M SEK

Turnover

8.33K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

7.5

2026

General meeting '26

7.5

2026

Interim report Q1'26

20.8

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press releaseyesterday

Lumito and Offspring Biosciences initiate pilot study to combine automated, standardised workflows with high‑sensitivity tissue analysis

Regulatory press release3/10/2026, 2:15 PM

Lumito publishes equity research report on Lumito

Regulatory press release3/10/2026, 10:45 AM

Lumito presents at Analyst Group’s and InFront Direkt Studios’ capital markets day

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release2/20/2026, 7:30 AM

Lumito AB publishes year-end report 2025

Regulatory press release2/18/2026, 8:20 AM

Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging

Regulatory press release2/17/2026, 2:00 PM

Invitation to webinar in connection with Lumito AB’s year-end report for 2025

Regulatory press release2/3/2026, 8:40 AM

Lumito initiates pilot project with leading professor in urological cancer research at Lund University

Regulatory press release1/30/2026, 2:45 PM

Lumito announces timetable for reverse share split and recalculated terms for outstanding warrants of series TO7

Regulatory press release1/29/2026, 8:15 AM

Lumito receives patent approval in India

Regulatory press release1/28/2026, 7:30 AM

Two Swedish research customers place orders for Lumito’s SCIZYS Erbium Kit

Regulatory press release1/23/2026, 1:50 PM

Lumito’s technology presented at The Pathological Society of Great Britain & Ireland Winter Meeting 2026

Regulatory press release1/20/2026, 3:30 PM

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

Regulatory press release1/13/2026, 8:30 AM

Analyst Group initiates coverage of Lumito

Regulatory press release1/12/2026, 8:15 AM

Lumito receives order from Swedish research unit

Regulatory press release1/8/2026, 12:00 PM

Lumito publishes investor letter – 2025 in review and the road ahead

Regulatory press release12/19/2025, 2:00 PM

The Board of Directors of Lumito proposes a reversed share split

Regulatory press release12/18/2025, 11:15 AM

Lumito’s technology enables quantification of low abundant cells

Regulatory press release12/12/2025, 8:00 AM

Lumito strengthens its international presence and participates in Digital Pathology & AI Congress Europe

Regulatory press release12/11/2025, 9:30 AM

Lumito renews its quality certification, ISO 13485:2016

Regulatory press release12/5/2025, 1:15 PM

Nomination Committee for Lumito appointed ahead of the 2026 Annual General Meeting

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.